Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients

Table 1

Baseline characteristics.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9
Age (years)	66	49	49	74	62	27	43	71	55
Sex	Female	Male	Male	Male	Female	Male	Female	Male	Female
Ethnicity	Asian	African American	African American	Caucasian	Hispanic	Asian	Asian	Hispanic	Asian
ESRD etiology	Hypertension	Hypertension	HIVAN	GN	Drug toxicity	GN	Lupus nephritis	Hypertension	Lupus nephritis
Number of kidney transplants	1	2	1	2	1	1	1	1	1
Donor type	Deceased	Deceased	Deceased	Living unrelated	Deceased	Living related	Deceased	Deceased	Deceased
HLA mismatches	6	5	5	3	5	2	4	6	6
Stent at transplant	No	No	No	No	Yes	No	No	No	No
Induction immunosuppression	Basiliximab	rATG	Basiliximab	rATG	rATG	Basiliximab	Basiliximab	Basiliximab	Basiliximab
Maintenance immunosuppression	MMF, Tac	MMF, Tac, Prd	MMF, CsA, Prd	MMF, Tac, Prd	MMF, Tac, PRD	MMF, Tac, Prd	MMF, Tac, Prd	MMF, Tac	MMF, Tac, Prd
Acute rejection prior to BKV (treatment)	No	No	No	No	No	No	No	Yes (steroids)	No

ESRD: end stage renal disease; HIVAN: human immunodeficiency virus associated nephropathy; GN: glomerulonephritis; HLA: human leukocyte antigen; rATG: rabbit antithymocyte globulin; DGF: delayed graft function; MMF: mycophenolate mofetil; Tac: tacrolimus; Prd: prednisone; CsA: cyclosporine.